U.S. Markets closed

Ionis Pharmaceuticals Inc (IONS) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Ionis Pharmaceuticals Inc (IONS) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Ionis Pharmaceuticals Inc is the RNA-targeted drug discovery and development company. Its broad pipeline consists of close to 32 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe, and rare diseases. Ionis Pharmaceuticals Inc has a market cap of $9.65 billion; its shares were traded at around $70.11 with a P/E ratio of 37.28 and P/S ratio of 16.10.


For the last quarter Ionis Pharmaceuticals Inc reported a revenue of $192.1 million, compared with the revenue of $161.3 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $599.7 million, an increase of 18.1% from last year. For the last five years Ionis Pharmaceuticals Inc had an average revenue growth rate of 32.4% a year.

The reported diluted earnings per share was $2.07 for the year, compared with the loss per share of $0.33 in the previous year. The Ionis Pharmaceuticals Inc had an operating margin of -10.23%, compared with the operating margin of 4.83% a year before. The 10-year historical median operating margin of Ionis Pharmaceuticals Inc is -24.68%. The profitability rank of the company is 5 (out of 10).

At the end of the fiscal year, Ionis Pharmaceuticals Inc has the cash and cash equivalents of $2.1 billion, compared with $129.6 million in the previous year. The long term debt was $633.0 million, compared with $605.9 million in the previous year. Ionis Pharmaceuticals Inc has a financial strength rank of 5 (out of 10).

At the current stock price of $70.11, Ionis Pharmaceuticals Inc is traded at 23.9% premium to its historical median P/S valuation band of $56.60. The P/S ratio of the stock is 16.10, while the historical median P/S ratio is 13.00. The stock gained 34.40% during the past 12 months.

CEO Recent Trades:

  • Chairman and CEO Stanley T Crooke sold 77,000 shares of IONS stock on 02/26/2019 at the average price of $60.77. The price of the stock has increased by 15.37% since.
  • Chairman and CEO Stanley T Crooke sold 46,904 shares of IONS stock on 02/13/2019 at the average price of $60.09. The price of the stock has increased by 16.67% since.

Directors and Officers Recent Trades:

  • SVP, Development Richard S Geary sold 999 shares of IONS stock on 02/13/2019 at the average price of $60. The price of the stock has increased by 16.85% since.
  • SVP Legal & General Counsel Patrick R. O'neil sold 275 shares of IONS stock on 02/12/2019 at the average price of $59.5. The price of the stock has increased by 17.83% since.
  • SVP Legal & General Counsel Patrick R. O'neil sold 19,600 shares of IONS stock on 02/05/2019 at the average price of $59.25. The price of the stock has increased by 18.33% since.
  • SVP, Antisense Research C Frank Bennett sold 9,013 shares of IONS stock on 02/01/2019 at the average price of $58.29. The price of the stock has increased by 20.28% since.

For the complete 20-year historical financial data of IONS, click here.

This article first appeared on GuruFocus.